United Therapeutics to take pulmonary hypertension drug to FDA for approval
Phase 3positiveralinepagPositive
AI Analysis
Summary
United Therapeutics reported positive Phase 3 results for ralinepag in pulmonary arterial hypertension, enabling an FDA approval request in 2026 with potential market launch in 2027.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Phase 3 study succeeded
Importance:8/10
Sentiment:
0.85
pulmonary hypertensionPhase 3 successFDA approval pathcommercial launch
Related Companies
Read the original article
Published by Endpoints News on March 2, 2026 4:24 PM